vimarsana.com

Latest Breaking News On - Alport syndrome foundation - Page 1 : vimarsana.com

New organ gives young man new hope

Certa Therapeutics investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases

Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data The research demonstrated that treatment with FT011 results in a remarkable reversal in the activation of genetic markers associated with fibrosis Fibrosis is responsible for 45 percent of all deaths globally - FT011 is a novel drug with potential to treat chronic fibrosis in multiple organs such as the kidneys, skin, lungs, heart, and eyes Certa Therapeutics is a clinical stage biotechnology company based in Melbourne, Australia, developing innovative therapies for the treatment of fibrotic diseases ANN ARBOR, Mich., Nov. 4, 2022 /PRNewswire/ New research presented today by the University of Michigan reveals ground-breaking results for Certa Therapeutics' FT011, a novel potential treatment of serious inflammatory and fibrotic diseases. The results in a chronic kid

Certa Therapeutics investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.